<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086510</url>
  </required_header>
  <id_info>
    <org_study_id>FMASUMD83/2021</org_study_id>
    <nct_id>NCT05086510</nct_id>
  </id_info>
  <brief_title>Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping</brief_title>
  <official_title>Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at comparing the recurrence rates of ventricular tachycardia ablated after&#xD;
      being mapped by 2 different techniques.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study participants are patients presented with recurrent ventricular tachycardia.&#xD;
&#xD;
      They will be divided into 2 groups in terms of mapping. The first group will use mapping&#xD;
      during sinus rhythm to identify late potentials that may be incriminated in the tachycardia&#xD;
      circuit.&#xD;
&#xD;
      The other group will undergo mapping during right ventricular extrastimulus pacing to unmask&#xD;
      hidden potentials. The identified potentials will be ablated in both groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 28, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with recurrence of ventricular tachycardia</measure>
    <time_frame>12 months</time_frame>
    <description>Recurrence of ventricular tachycardia implies receiving at least one appropriate implantable cardioverter defibrillator therapy or hospital admission due to symptomatic ventricular tachycardia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants receiving at least one appropriate implantable cardioverter defibrillator therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Appropriate therapies include anti tachycardia pacing and shocks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to first recurrence of ventricular tachycardia</measure>
    <time_frame>12 months</time_frame>
    <description>This will be measured from the end of the ablation procedure till the first documented recurrence of ventricular tachycardia whether by electrocardiogram or by device tracings</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience sudden cardiac death</measure>
    <time_frame>12 months</time_frame>
    <description>This is defined as unexpected death where a cardiac cause is the most probable etiology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who die from any cause (All-cause mortality)</measure>
    <time_frame>12 months</time_frame>
    <description>This includes death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations for heart failure per participant</measure>
    <time_frame>12 months</time_frame>
    <description>This denotes hospital admission due to new or worsening symptoms of heart failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Tachycardia, Ventricular</condition>
  <arm_group>
    <arm_group_label>Sinus Rhythm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will undergo mapping during sinus rhythm to identify and ablate late potentials that may be incriminated in the tachycardia circuit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sense protocol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will undergo mapping during right ventricular single extrastimulus pacing to identify and thus ablate potentials that might have been masked during sinus rhythm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>Both groups will undergo radiofrequency ablation of potentials likely responsible for the tachycardia. Those potentials are identified by the formentioned 2 distinct methods.</description>
    <arm_group_label>Sense protocol group</arm_group_label>
    <arm_group_label>Sinus Rhythm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Patients with structural heart disease; previous myocardial infarction, left&#xD;
             ventricular dilatation/systolic dysfunction, or normal left ventricular diameters/&#xD;
             systolic function with evidence of ventricular scar on contrast enhanced-cardiac&#xD;
             magnetic resonance or electroanatomic map.&#xD;
&#xD;
               -  Sustained monomorphic ventricular tachycardia documented by 12-lead ECG or&#xD;
                  implantable cardioverter defibrillator (electrograms resistant to antiarrhythmic&#xD;
                  drug treatment or requiring implantable cardioverter defibrillator therapies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Patients with ventricular arrhythmias attributed to reversible causes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad G Elewa</last_name>
    <role>Principal Investigator</role>
    <affiliation>AinShams university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohammad G Elewa, Master</last_name>
    <phone>+201019811895</phone>
    <email>mdgamal92@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AinShams university hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Mohammad G Elewa, Master</last_name>
      <phone>+201019811895</phone>
      <email>mdgamal92@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Mohammad Gamal</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

